| 货号 | 15425-5mg |
| 描述 | Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM; IC50 = 1.8 μM), which is the main receptor responsible for ADP-induced platelet aggregation.1,2 It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding.3 Ticagrelor has been studied for its application in antiplatelet therapy to prevent ischemic cardiac complications associated with cardiovascular diseases.4 |
| 别名 | AR-C 126532XX;AZD 6140;Brilinta®;Brilique™; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Zech, G.,Hessler, G.,Evers, A., et al. Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone. Journal of Medicinal Chemistry 55(20), 8615-8629 (2012). 2.Michelson, A.D. Advances in antiplatelet therapy. Hematology Am.Soc.Hematol.Educ.Program 2011, 62-69 (2011). 3.Wallentin, L. P2Y12 inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal 30(16), 1964-1977 (2009). 4.Davis, E.M.,Knezevich, J.T. and Teply, R.M. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: A review of ticagrelor. Clin.Pharmacol. 5, 67-83 (2013). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 522.6 |
| 分子式 | C23H28F2N6O4S |
| CAS号 | 274693-27-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |